Epclusa, INN-Sofosbuvir/Velpatasvir
Total Page:16
File Type:pdf, Size:1020Kb
26 May 2016 EMA/399285/2016 Committee for Medicinal Products for Human Use (CHMP) Assessment report Epclusa International non-proprietary name: sofosbuvir / velpatasvir Procedure No. EMEA/H/C/004210/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 7 1.1. Submission of the dossier ...................................................................................... 7 1.2. Steps taken for the assessment of the product ......................................................... 8 2. Scientific discussion ................................................................................ 9 2.1. Introduction......................................................................................................... 9 2.2. Quality aspects .................................................................................................. 10 2.2.1. Introduction .................................................................................................... 10 2.2.2. Active substance ............................................................................................ 10 2.2.3. Finished medicinal product ................................................................................ 15 2.2.4. Discussion on chemical, and pharmaceutical aspects ............................................ 18 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects ...................... 18 2.2.6. Recommendation for future quality development ................................................. 18 2.3. Non-clinical aspects ............................................................................................ 19 2.3.1. Introduction .................................................................................................... 19 2.3.2. Pharmacology ................................................................................................. 20 2.3.3. Pharmacokinetics............................................................................................. 25 2.3.4. Toxicology ...................................................................................................... 37 2.3.5. Ecotoxicity/environmental risk assessment ......................................................... 47 2.3.6. Discussion on non-clinical aspects...................................................................... 50 2.3.7. Conclusion on the non-clinical aspects ................................................................ 50 2.4. Clinical aspects .................................................................................................. 51 2.4.1. Introduction .................................................................................................... 51 2.4.2. Pharmacokinetics............................................................................................. 53 2.4.3. Discussion on clinical pharmacology ................................................................... 66 2.4.4. Conclusions on clinical pharmacology ................................................................. 70 2.5. Clinical efficacy .................................................................................................. 70 2.5.1. Dose response studies...................................................................................... 71 2.5.2. Main studies ................................................................................................... 73 2.5.3. Discussion on clinical efficacy ............................................................................ 87 2.5.4. Conclusions on the clinical efficacy ..................................................................... 89 2.6. Clinical safety .................................................................................................... 89 2.6.1. Discussion on clinical safety ............................................................................ 101 2.6.2. Conclusions on the clinical safety ..................................................................... 102 2.7. Risk Management Plan ...................................................................................... 102 2.8. Pharmacovigilance ............................................................................................ 108 2.9. Product information .......................................................................................... 108 2.9.1. User consultation ........................................................................................... 108 2.9.2. Additional monitoring ..................................................................................... 108 Assessment report EMA/399285/2016 Page 2/112 3. Benefit-Risk Balance............................................................................ 108 4. Recommendations ............................................................................... 111 Assessment report EMA/399285/2016 Page 3/112 List of abbreviations ALT alanine aminotransferase APRI AST to Platelet Ratio Index ARV antiretroviral AST aspartate aminotransferase ATV atazanavir AUC area under the plasma/serum concentration vs. time curve AUCtau area under the plasma/serum concentration vs. time curve over the dosing interval CatA cathepsin A CL/F apparent oral clearance after administration of the drug: Cmax maximum observed plasma/serum concentration of drug Ctau observed drug concentration at the end of the dosing interval BCRP breast cancer resistance protein BCS Biopharmaceutics Classification System BSEP bile salt export pump CLcr creatinine clearance COBI, cobicistat (Tybost) CPT Child-Pugh-Turcotte CsA cyclosporine (cyclosporin A) DAA direct-acting antiviral DCV daclatasvir (BMS-790052) DDI drug-drug interaction DILI drug-induced liver injury DRV darunavir DSC Differential Scanning Calorimetry DTG dolutegravir EC European Commission EC50 concentration of a compound inhibiting virus replication by 50% E/C/F/TAF elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (coformulated) eGFR estimated glomerular filtration rate EFV efavirenz EU European Union EVG elvitegravir (Vitekta) EVG/COBI/FTC/TDF elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (coformulated; Stribild) FDC fixed-dose combination FTC, emtricitabine FTC/RPV/TDF emtricitabine/rilpivirine/tenofovir disoproxil fumarate (coformulated; Complera/Eviplera) FTC/TDF emtricitabine/tenofovir disoproxil fumarate (coformulated; Truvada) GC Gas Chromatography GT genotype GVS Gravimetric vapour sorption Assessment report EMA/399285/2016 Page 4/112 H2RA H2-receptor antagonist HBV hepatitis B virus HCV hepatitis C virus HDPE high-density polyethylene HIV, HIV-1 human immunodeficiency virus, type 1 HMG-CoA 3-hydroxy-3-methylglutaryl-coenzyme A HPLC High performance liquid chromatography IC50 concentration that results in 50% inhibition ICH International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use ICP-OES Inductively coupled plasma-optical emission spectroscopy IFN interferon IFN-α interferon-alpha IR Infrared Ka apparent first-order absorption rate constant LDV ledipasvir LDV/SOF ledipasvir/sofosbuvir (coformulated; Harvoni) LLOQ lower limit of quantitation LPV lopinavir MATE1 multidrug and toxin extrusion 1 MELD model for end-stage liver disease MRP2 multidrug resistance-associated protein 2 NMR Nuclear Magnetic Resonance NOAEL no observed adverse effect level NOEL no observed effect level NOR Normal Operating Range NS (3/4A/5A/5B) nonstructural protein (3/4A/5A/5B) NTCP sodium-taurocholate cotransporter protein OAT organic anion transporter OATP organic anion transporter polypeptide OCT organic cation transporter PAR Proven Acceptable Range PDE Permitted Daily Exposure Peg-IFN pegylated interferon Ph. Eur. European Pharmacopoeia P-gp P-glycoprotein PMI Potentially mutagenic impurities PPI proton pump inhibitor /r boosted with ritonavir QbD Quality by design RAL raltegravir Assessment report EMA/399285/2016 Page 5/112 RAV resistance-associated variant RBV ribavirin RH Relative Humidity ROI Residue on ignition RPV rilpivirine RTV ritonavir SmPC Summary of Product Characteristics SOF sofosbuvir (GS-7977; Sovaldi) SOF/VEL sofosbuvir/velpatasvir (coformulated) SVR, SVRxx sustained virologic response, sustained virologic response, sustained virologic response at “xx” weeks following completion of all treatment TAF tenofovir alafenamide TDF tenofovir disoproxil fumarate TE treatment experienced TFV tenofovir TN treatment naïve TSE Transmissible Spongiform Encephalopathy UGT1A1 uridine disphosphate glucuronosyltransferase 1A1 ULN upper limit of normal range UPLC ultra-high performance liquid chromatography UV Ultraviolet VEL velpatasvir (GS-5816) Assessment report EMA/399285/2016 Page 6/112 1. Background information on the procedure 1.1. Submission of the dossier The applicant Gilead Sciences International Ltd submitted on 14 November 2015 an application for Marketing Authorisation to the European Medicines Agency (EMA) for Epclusa, through the centralised procedure falling within the Article 3(1) and point 3 of Annex